Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant
Conferences
Ark, JI; Nyberg, W; Simon, K; Rosales, A; Clouden, S; Eyquem, J; Asokan, A
Published in: MOLECULAR THERAPY
April 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
April 2022
Volume
30
Issue
4
Start / End Page
425 / 426
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
Citation
APA
Chicago
ICMJE
MLA
NLM
Ark, J. I., Nyberg, W., Simon, K., Rosales, A., Clouden, S., Eyquem, J., & Asokan, A. (2022). Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant. In MOLECULAR THERAPY (Vol. 30, pp. 425–426).
Ark, Jonathan I., William Nyberg, Katherine Simon, Alan Rosales, Sylvanie Clouden, Justin Eyquem, and Aravind Asokan. “Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant.” In MOLECULAR THERAPY, 30:425–26, 2022.
Ark JI, Nyberg W, Simon K, Rosales A, Clouden S, Eyquem J, et al. Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant. In: MOLECULAR THERAPY. 2022. p. 425–6.
Ark, Jonathan I., et al. “Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant.” MOLECULAR THERAPY, vol. 30, no. 4, 2022, pp. 425–26.
Ark JI, Nyberg W, Simon K, Rosales A, Clouden S, Eyquem J, Asokan A. Targeted In Vivo Manipulation of Murine T-Cells Using a Newly Evolved AAV Capsid Mutant. MOLECULAR THERAPY. 2022. p. 425–426.
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
April 2022
Volume
30
Issue
4
Start / End Page
425 / 426
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics